Enlivex Therapeutics (ENLV) announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21-23, 2025 in Tel Aviv, Israel. The Company’s presentation is titled “Enlivex-Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases” and will be delivered by the Company’s CEO on May 21st as part of the session “Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases”. Allocetra, Enlivex’s universal, off-the-shelf cell therapy, is designed to reset macrophages-key immune cells-to their homeostatic, or “balanced,” state. Non-homeostatic macrophages are implicated in a broad range of chronic and life-threatening diseases, and Allocetra’s unique reprogramming capability may offer a promising strategy for immune system rebalancing and disease resolution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Therapeutics files $300M mixed securities shelf
- Enlivex’s Promising Clinical Progress and Strategic Collaborations Justify Buy Rating
- Enlivex to Present Allocetra™ Insights at OARSI 2025
- Enlivex Completes Phase II Enrollment for Osteoarthritis Trial
- Enlivex completed enrollment of patients in Phase II trial of Allocetra